Stay updated with breaking news from Liquidia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
McAdam LLC lessened its position in shares of Liquidia Co. (NASDAQ:LQDA – Free Report) by 72.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,244 shares of the company’s stock after selling 37,073 shares during the quarter. McAdam LLC’s holdings in Liquidia […] ....
Liquidia Co. (NASDAQ:LQDA – Get Free Report)’s share price fell 6.5% during mid-day trading on Monday . The stock traded as low as $15.61 and last traded at $15.64. 672,091 shares changed hands during trading, a decline of 30% from the average session volume of 956,830 shares. The stock had previously closed at $16.73. Analyst […] ....
The FDA was expected to make its decision by Wednesday, but it is still reviewing Liquidia's marketing application for possible approval, although it has not asked for any additional clinical data to support the application. The North Carolina-based company was seeking the health regulator's nod to expand the use of its drug to also treat pulmonary hypertension associated with interstitial lung disease (PH-ILD), a group of disorders that cause scarring in the lungs. The drug was granted tentative approval in 2021 to treat pulmonary arterial hypertension (PAH) to improve adult patients' ability to exercise. ....
Biotechnology company, Liquidia Corp. (LQDA) stock gained 9% on Thursday following announcement of a total of $100 new financings from Patient Square Capital and Healthcare Royalty. ....